Selective serotonin reuptake inhibitor

Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression

Retrieved on: 
Wednesday, March 27, 2024

Vancouver, Canada, March 27, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced that it has submitted its tenth patent application under the international Patent Cooperation Treaty (“PCT”), as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Key Points: 
  • The patent applications refer to the novel proprietary composition of Clearmind’s MEAI compound (5-methoxy-2-aminoindane) with Palmitoylethanolamide (“PEA”), the active ingredient of SciSparc’s proprietary CannAmide™, for preventing and/or treating depression.
  • This application was previously filed as provisional patent application with the United States Patent and Trademark Office (“USPTO”).
  • Under our collaboration with SciSparc, we believe that our proprietary drugs can positively impact patients dealing with various forms of depression including treatment resistant depression," stated Dr. Adi Zuloff-Shani, CEO of Clearmind.
  • "We further believe that we have a tremendous opportunity to develop viable alternatives to the current SSRIs for individuals living with depression.

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Retrieved on: 
Thursday, March 21, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced the release of the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder.

Key Points: 
  • In September 2023, Bionomics reported the topline results for the Phase 2b ATTUNE trial of BNC210 in patients with PTSD demonstrating that the trial met its primary endpoint and several secondary endpoints, and that BNC210 was generally well tolerated.
  • The full data analysis is detailed below and in an accompanying presentation of the results that is posted on the Company’s website .
  • “The full results of the ATTUNE Phase 2b trial further strengthen, the already compelling, topline results and position BNC210 as a potential highly differentiated treatment with rapid onset and durable efficacy that could improve outcomes for patients with PTSD.
  • Following the ATTUNE Phase 2b trial readout and based on a safety database of ~600 patients, BNC210 continues to demonstrate a non-sedating, non-habit forming, non-cognition impairing psychoactive profile.

Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Retrieved on: 
Friday, March 15, 2024

“Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.

Key Points: 
  • “Initiation of the Phase 2 study of CYB004 for GAD is an exciting step forward for our deuterated DMT program,” said Doug Drysdale, Chief Executive Officer of Cybin.
  • The CYB004-002 Phase 2 study is a randomized, double-blind study which will evaluate the safety and efficacy of CYB004 in participants with GAD, with concomitant antidepressant/anxiolytic treatment and co-morbid depression allowed.
  • The study will enroll participants with moderate to severe GAD and a score of ≥10 on the GAD-7 anxiety scale.
  • Global, regional and national burden of anxiety disorders from 1990 to 2019: results from the Global Burden of Disease Study 2019.

Why are so many Australians taking antidepressants?

Retrieved on: 
Thursday, February 8, 2024

Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.

Key Points: 
  • Around one in seven Australians take antidepressants; more than 3.5 million of us had them dispensed in 2021–22.
  • Guidelines mostly recommend antidepressants for more severe depression and anxiety but not as first-line treatment for less severe depression.
  • So why are so many Australians taking antidepressants and why are prescriptions rising?

Enter the antidepressant ‘blockbusters’

  • In the 1990s, pharmaceutical companies heavily promoted new selective serotonin reuptake inhibitors (SSRI) antidepressants, including Prozac (fluoxetine), Zoloft (sertraline) and Lexapro (escitalopram).
  • These drugs were thought to be less dangerous in overdoses and seemed to have fewer side effects than the tricyclic antidepressants they replaced.
  • Pharmaceutical companies marketed SSRIs energetically and often exaggerated their benefits, including by paying “key opinion leaders” – high-status clinicians to promote them.

Why are antidepressants prescribed?

  • GPs also prescribe antidepressants to patients experiencing distress but who don’t have a psychiatric diagnosis.
  • Another, who cried when informed she had breast cancer, was immediately offered a prescription for antidepressants.
  • Most patients believe antidepressants restore a chemical imbalance that underpins depression.
  • Antidepressants are emotional (and sexual) numbing agents – sometimes sedating, sometimes energising.
  • Around half of users have impaired sexual function and for some, this sexual dysfunction persists after stopping antidepressants.

How long do people take antidepressants?

  • Around half of patients who start antidepressants don’t like them and stop within weeks.
  • Of those who do take them for months, many continue to use them indefinitely, often for many years.
  • Read more:
    Antidepressants can cause withdrawal symptoms – here’s what you need to know

We need to adjust how we view mental distress

  • Overprescribing antidepressants is a symptom of our lack of attention to the social determinants of mental health.
  • GPs also need to ensure they discuss with their patients the potential adverse effects of antidepressants, and when and how to safely stop them.
  • But the fundamental problem is social and can only be properly addressed by meaningfully addressing inequality and changing community attitudes to distress.


Jon Jureidini receives research funding from MMRF. He is affiliated with Critical Psychiatry Network Australasia.

Global Narcolepsy Drugs Market Research Report 2024: Pipeline Analysis, Key Company Profiles and Recent Developments 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024

The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market has witnessed significant growth in recent years owing to the rising prevalence of narcolepsy and increased awareness about the condition.
  • Latin America and Middle East & Africa are competing closely to grab the maximum share of the global narcolepsy drugs market.
  • Global Narcolepsy Drugs Market - Key Company Profiles, Recent Developments, Financial Insights

Levium Is Recognized by Optimal Health News as the Best Natural Anti-Anxiety Supplement of 2024

Retrieved on: 
Tuesday, January 30, 2024

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Optimal Health News has announced Levium as the recipient of the Best Natural Anti-Anxiety Supplement of 2024 award. A safe and effective nutraceutical, Levium offers an alternative to prescription medications, using all-natural ingredients that balance neurotransmitters to help reduce anxiety and improve the response to stress. [See full press release.]

Key Points: 
  • Levium, a natural anxiety relief supplement developed by Glauser Life Sciences, Inc., has won the award for the Best Natural Anti-Anxiety Supplement of 2024 from Optimal Health News, a digital publication.
  • It accomplishes this through natural, clinically proven ingredients that are non-addictive and safe to use in conjunction with common prescription medications.
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- Optimal Health News has announced Levium as the recipient of the Best Natural Anti-Anxiety Supplement of 2024 award.
  • This growth is driven by the rising incidence of anxiety-related illnesses and increasing government initiatives to promote mental health awareness.

Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs

Retrieved on: 
Thursday, January 4, 2024

The first quarter of 2024 should be another active and productive period for us, as we advance our clinical programs.

Key Points: 
  • The first quarter of 2024 should be another active and productive period for us, as we advance our clinical programs.
  • For our dDMT programs, we plan to initiate a Phase 2 trial of CYB004 in generalized anxiety disorder (“GAD”),” said Doug Drysdale, Chief Executive Officer of Cybin.
  • “As we look ahead, we see enormous opportunities for progress across our differentiated programs and development pipeline.
  • Upcoming Milestones for dDMT Program:
    Phase 1 topline data for CYB004 expected early Q1 2024.

Mikra Receives First Shipment of Serenity, an Innovative Mental Health Product for Anxiety, in Time for Black Friday

Retrieved on: 
Wednesday, November 22, 2023

TORONTO, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough ventures that transform human wellness, is pleased to report that its U.S. biosciences subsidiary Mikra Cellular Sciences Inc. (“Mikra”) has received the first shipment of Serenity, a natural supplement for supporting symptoms of anxiety, at its warehouse in California in time for sale on Black Friday, November 24. To order Serenity starting this Friday, customers should visit wearemikra.com and are encouraged to sign up for updates and promotional offers at https://bit.ly/serenity-sign-up.

Key Points: 
  • To order Serenity starting this Friday, customers should visit wearemikra.com and are encouraged to sign up for updates and promotional offers at https://bit.ly/serenity-sign-up .
  • Now, a small but vocal group of patients is speaking out about severe sexual problems that have endured even long after they stopped taking selective serotonin reuptake inhibitors...
  • The drugs’ effects have been devastating, they said, leaving them unable to enjoy sex or sustain romantic relationships."
  • With Lifeist's expertise with fragrant and flavorful botanicals, Serenity is poised to become the best tasting lavender oil extract supplement on the market.

Global Premature Ejaculation Therapeutics Market Insights Report 2024-2029 Featuring Prominent Vendors - Plethora Solutions, Pfizer, Eli Lilly and Co, GSK, Menarini - ResearchAndMarkets.com

Retrieved on: 
Monday, December 11, 2023

This report offers market size & forecast data for the global premature ejaculation therapeutics market.

Key Points: 
  • This report offers market size & forecast data for the global premature ejaculation therapeutics market.
  • This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.
  • The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029.
  • Plethora Solutions, Pfizer, Eli Lilly and Company, GSK plc, and the Menarini group are some leading players currently dominating the global premature ejaculation therapeutics market.

Guidance Statement for Mental Health Symptoms of Long COVID Announced by the American Academy of Physical Medicine and Rehabilitation

Retrieved on: 
Wednesday, November 8, 2023

Long COVID can cause new mental health symptoms, worsen existing mental health conditions, or mimic other LC symptoms.

Key Points: 
  • Long COVID can cause new mental health symptoms, worsen existing mental health conditions, or mimic other LC symptoms.
  • Long COVID can cause new mental health symptoms and can also worsen existing mental health conditions or mimic other Long COVID symptoms.
  • "There really is some nuance in looking at the mental health symptoms of Long COVID because Long COVID symptoms that are related to mental health can also exacerbate or mimic other symptoms of Long COVID, such as fatigue, brain fog, and sleep disturbances," said Abby Cheng, MD, FAAPMR, author of the guidance.
  • Traditional nonpharmacologic and pharmacologic mental health treatments, such as SSRIs, should be considered in tandem for treating mental health symptoms of Long COVID.